Mark Pinkerton

Nexomics Biosciences

Nexomics Biosciences focuses on the discovery, development and commercialization of novel drugs focusing on cancer, antiviral and antibiotic treatments. Nexomics Biosciences also functions as a contract research organization (CRO), offering a broad array of gene-to-structure services to the biopharmaceutical community. We offer a variety of services from bioinformatics target profiling, gene cloning, recombinant protein expression, laboratory-scale fermentation, crystallization, NMR structural studies, X-ray crystallography structural studies, assay development, and functional annotation. Nexomics Biosciences aims to build a portfolio of intellectual property associated with structure-based assay development, protein production, and drug discovery. Our long term goal is development of a proprietary pharmaceutical discovery program based on characterizing disease related proteins and their molecular functions, and by identifying potential drug target binding compounds.